Lyme Disease Market Report: Market Size & Forecast 2026

Lyme borreliosis is a multisystem inflammatory infection caused primarily by Borrelia burgdorferi, transmitted to humans through the bites of infected Ixodes ticks. The condition typically progresses through stages, from early localized infection with characteristic erythema migrans rash to disseminated and late-stage disease affecting joints, the heart, and the nervous system if untreated. The market addresses this burden through diagnostic tests (ELISA, Western blot, PCR), antibiotic-based treatment regimens (doxycycline, amoxicillin, cefuroxime), and ongoing vaccine research efforts.

• •Standard antibiotic treatment includes oral doxycycline, amoxicillin, or cefuroxime axetil for early-stage disease, with intravenous ceftriaxone reserved for neurological or cardiac involvement
• •Diagnosis relies on a two-tiered serological testing approach: an initial ELISA followed by Western blot confirmation, though early-stage testing can yield false negatives
• •The disease is most prevalent in North America, Europe, and parts of Asia, with the United States reporting approximately 30,000 to 40,000 confirmed cases annually through CDC surveillance

Rising incidence of Lyme disease across previously low-risk regions, driven in part by climate change expanding tick habitats and longer active seasons, is a primary market catalyst. Increased awareness among both healthcare professionals and the general population has led to higher diagnosis rates and earlier treatment initiation. Government initiatives for surveillance, prevention, and research funding have intensified, particularly in endemic regions of North America and Europe.

• •Climate change and warmer winters have expanded the geographic range of Ixodes tick populations into new regions of North America and Europe, increasing the at-risk population
• •Improved diagnostic technologies, including next-generation PCR and point-of-care testing, are enabling faster and more accurate detection of Borrelia infections
• •Growing investment in vaccine development, including candidates from Pfizer and Valneva, reflects renewed commercial and public health interest in primary prevention

The market is typically segmented by product type into diagnostics, therapeutics, and preventive vaccines, with diagnostics representing the largest segment due to the critical role of early and accurate detection. Geographically, North America, particularly the United States, dominates market share due to high disease prevalence and established healthcare infrastructure, while Europe represents a significant and growing market driven by widespread endemicity across Central and Northern European countries.

• •North America holds the largest market share, supported by the high incidence of Lyme disease in the northeastern and upper midwestern United States and a well-developed diagnostic ecosystem
• •Europe is a key growth region, with Germany, France, and the Netherlands reporting some of the highest incidence rates on the continent, alongside strong publicly funded healthcare systems
• •The Asia-Pacific region, while smaller in current market size, is emerging as an area of interest due to expanding tick populations in China, Japan, and South Korea

What are the recent trends and outlook?

The market is positioned for sustained growth through the latter half of the decade, supported by anticipated regulatory approvals of new vaccine candidates and ongoing improvements in diagnostic accuracy. The development of pan-European surveillance networks and harmonized diagnostic guidelines is expected to standardize care and expand market access. Increasing recognition of post-treatment Lyme disease syndrome is also driving research into novel therapeutic approaches beyond conventional antibiotic regimens.

• •The anticipated approval of VLA15 could represent a landmark addition to the market, addressing the longstanding absence of a commercially available human Lyme vaccine in the United States since 2002
• •Advances in point-of-care molecular diagnostics and next-generation serological assays aim to close the diagnostic gap in early infection, potentially capturing cases that conventional two-tier testing misses
• •Growing interest in understanding and treating post-treatment Lyme disease syndrome is expected to drive investment in new therapeutic research and expand the overall addressable market